<?xml version="1.0"?>
<Articles JournalTitle="Journal of Pharmaceutical Care">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Journal of Pharmaceutical Care</JournalTitle>
      <Issn>2322-4630</Issn>
      <Volume>13</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2025</Year>
        <Month>12</Month>
        <Day>01</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Investigation of Genetic Polymorphisms of Cytochrome P450 2C19 in Iranian Patients with Drug-Eluting Stents</title>
    <FirstPage>171</FirstPage>
    <LastPage>179</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Mahdiye</FirstName>
        <LastName>Abiyarghamsari</LastName>
        <affiliation locale="en_US">Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Farshad</FirstName>
        <LastName>Hoseini-Shirazi</LastName>
        <affiliation locale="en_US">Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammad</FirstName>
        <LastName>Sistanizad</LastName>
        <affiliation locale="en_US">Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2025</Year>
        <Month>05</Month>
        <Day>04</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2025</Year>
        <Month>08</Month>
        <Day>19</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Cytochrome P450 2C19 (CYP2C19) exhibits polymorphism, with about 21 known allelic variants. Notably, the *17 allele is associated with increased enzymatic activity, culminating in enhanced CYP2C19 activity and the ultra-rapid metabolizer (UM) phenotype. This genetic variation has a profound impact on an individual's response to a wide range of medications. The primary objective of this study was to ascertain the prevalence of the CYP2C19*17 allele among Iranian patients who have received drug-eluting stents.
&#xD;

Methods: This study was conducted to examine the genetic polymorphism of the CYP2C19 enzyme in 100 patients with drug-eluting stents (DESs) at Imam Hossein Hospital, Tehran, Iran. All participants were selected based on pre-defined inclusion criteria. Blood samples were obtained for DNA extraction, and CYP2C19 genotypes were subsequently analyzed through polymerase chain reaction (PCR) and gel electrophoresis.
&#xD;

Results: The *17 polymorphism was detected in 11% of the cohort. Of this group, 11 individuals were heterozygous carriers of the CYP2C19*17 allele, whereas the homozygous *17/*17 genotype was not observed in any participant.
&#xD;

Conclusion: Our findings demonstrate a low prevalence of the CYP2C19*17 allele and an absence of the homozygous *17/*17 genotype in the Iranian population. Despite its lower prevalence compared to other populations, the clinical implications of this allele are still considered highly significant.</abstract>
    <web_url>https://jpc.tums.ac.ir/index.php/jpc/article/view/837</web_url>
    <pdf_url>https://jpc.tums.ac.ir/index.php/jpc/article/download/837/428</pdf_url>
  </Article>
</Articles>
